Director of the AIDS program reviews "abuse of power" manufacturers Cocktail
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Rio de Janeiro - The readjustment of prices for medicines for AIDS and a model of the female condom - the values nearly doubled for the Ministry of Health between a purchase and others - were harshly criticized Tuesday (12) by the director of the National STD and AIDS, said Simao, who described the attitude of the manufacturers as "clear abuse of power" economical.
During a seminar in Rio de Janeiro, the director cited the increasing price of condoms made of nitrile rubber and marketed by British Female Health Company, and the drug nevirapine, used to treat 400 children with AIDS in the country.
Within the last purchase of the government in 2006 and the proposal presented today to the ministry during the trading session in Brasilia, the cost of condoms increased from $ 1.56 to $ 2.70. Since the drug's only sold in Brazil by Germany's Boehringer Ingelheim has readjustment of 87% and went from $ 19 to $ 34 between 2008 and 2009.
"This is clearly abuse of power. Both by Boehringer [Ingelheim] and by the Female [Health Company], "said the director, during a seminar on access to antiretrovirals in Rio
According to Simao, the ministry suspended the session that negotiated the purchase of condoms and said that Brazil can buy products from other brands. "The government wants to allow the access of women to a method that they dominate, but at an acceptable cost," he said.
The distribution of condoms in Brazil reports that there was no price adjustment. The company says the product is more expensive because it will no longer be imported directly by the government. "The import will be made by a distributor and now involves costs to taxes, storage and customer service," said U.S. Trade Representative Female, Geraldo Mattar.
According to the director of the AIDS program, negotiating with Boehringer to buy the dose infant nevirapine was also closed. The lab claims that, last year, the sale was made at a discount and that the current price below its foreign policy. Because of this obstacle, Brazil could seek alternatives such as generics approved by the World Health Organization (WHO).
For the director of the ministry, the monopoly of industry and the constraints of the patent system can impede access to health care. "When we have only one producer, we can abuse power," he stressed.
She questions the validity of 20 years for a patent as a way to tackle the problem and collecting the WHO to encourage countries to upgrade the flexibility mechanisms of industrial properties, provided for in international agreements.
Among those strategies is compulsory licensing, followed by Brazil to efavirenz in 2007. With the decision, Brazil began to produce it in Farmanguinhos for $ 0.63. Before, the country was paying per pill U.S. $ 1.56 to Merck.
Source: The Afternoon
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Important:
The JurisWay site does not interfere in the work provided by doctrine, why only reflect the opinions, ideas and concepts of their authors.
